Authors:
MARKMAN M
ROSE PG
JONES E
HOROWITZ IR
KENNEDY A
WEBSTER K
BELINSON J
FUSCO N
FLUELLEN L
KULP B
PETERSON G
MCGUIRE WP
Citation: M. Markman et al., 96-HOUR INFUSIONAL PACLITAXEL AS SALVAGE THERAPY OF OVARIAN-CANCER PATIENTS PREVIOUSLY FAILING TREATMENT WITH 3-HOUR OR 24-HOUR PACLITAXEL INFUSION REGIMENS, Journal of clinical oncology, 16(5), 1998, pp. 1849-1851
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., PACLITAXEL ADMINISTRATION TO GYNECOLOGIC CANCER-PATIENTS WITH MAJOR CARDIAC RISK-FACTORS, Journal of clinical oncology, 16(11), 1998, pp. 3483-3485
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., EVIDENCE THAT A TREATMENT-FREE INTERVAL OF LESS-THAN 6 MONTHS DOES NOT EQUATE WITH CLINICALLY DEFINED PLATINUM RESISTANCE IN OVARIAN-CANCEROR PRIMARY PERITONEAL CARCINOMA, Journal of cancer research and clinical oncology, 124(6), 1998, pp. 326-328
Authors:
MARKMAN M
KENNEDY A
SUTTON G
HURTEAU J
WEBSTER K
PETERSON G
KULP B
BELINSON J
Citation: M. Markman et al., PHASE-2 TRIAL OF SINGLE-AGENT IFOSFAMIDE MESNA IN PATIENTS WITH PLATINUM/PACLITAXEL REFRACTORY OVARIAN-CANCER WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH AN ALKYLATING AGENT/, Gynecologic oncology (Print), 70(2), 1998, pp. 272-274
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
PETERSON G
KULP B
BELINSON J
Citation: M. Markman et al., SIMPLIFIED REGIMEN FOR THE PREVENTION OF PACLITAXEL-ASSOCIATED HYPERSENSITIVITY REACTIONS, Journal of clinical oncology, 15(12), 1997, pp. 3517-3517
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
PETERSON G
KULP B
BELINSON J
Citation: M. Markman et al., LOW-DOSE INTRAVENOUS ONDANSETRON (8 MG) PLUS DEXAMETHASONE - AN EFFECTIVE REGIMEN FOR THE CONTROL OF CARBOPLATIN-INDUCED EMESIS, Journal of cancer research and clinical oncology, 123(4), 1997, pp. 224-226
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., CARBOPLATIN PLUS PACLITAXEL IN THE TREATMENT OF GYNECOLOGIC MALIGNANCIES - THE CLEVELAND CLINIC EXPERIENCE, Seminars in oncology, 24(5), 1997, pp. 26-29
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., CONTINUED CHEMOSENSITIVITY TO CISPLATIN CARBOPLATIN IN OVARIAN-CARCINOMA DESPITE TREATMENT WITH MULTIPLE PRIOR PLATINUM-BASED REGIMENS/, Gynecologic oncology, 65(3), 1997, pp. 434-436
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF MESNA TO PREVENT IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITIS, Seminars in oncology, 23(3), 1996, pp. 97-98
Authors:
CONNELLY E
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: E. Connelly et al., PACLITAXEL DELIVERED AS A 3-HR INFUSION WITH CISPLATIN IN PATIENTS WITH GYNECOLOGIC CANCERS - UNEXPECTED INCIDENCE OF NEUROTOXICITY, Gynecologic oncology, 62(2), 1996, pp. 166-168
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., CONTROL OF CARBOPLATIN-INDUCED EMESIS WITH A FIXED LOW-DOSE OF GRANISETRON (0.5 MG) PLUS DEXAMETHASONE, Gynecologic oncology, 60(3), 1996, pp. 435-437
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., PACLITAXEL (T) GIVEN AS A 3-HOUR (HR) INFUSION ALONG WITH CISPLATIN (C) IN PATIENTS (PTS) WITH GYNECOLOGIC CANCERS, Clinical research, 42(2), 1994, pp. 10000342-10000342